睿昂基因(688217.SH)2025年度归母净亏损4988.36万元

Core Viewpoint - Ruiang Gene (688217.SH) reported a significant decline in revenue and increased net losses for the fiscal year 2025, attributed to intensified competition in the in vitro diagnostics industry and specific events affecting the company [1] Financial Performance - The company achieved total operating revenue of 174 million yuan, representing a year-on-year decrease of 28.19% [1] - The net loss attributable to shareholders of the parent company was 49.8836 million yuan [1] - The net loss attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 58.2004 million yuan [1] - Basic loss per share was 0.9 yuan [1] Industry Context - The decline in revenue is linked to increased competition within the in vitro diagnostics sector [1] - The company's performance was also impacted by specific events that occurred during the reporting period [1]